Aoife Brennan - 07 Jun 2023 Form 4 Insider Report for FIBROGEN INC (FGEN)

Reporting relationship: Director
Issuer ticker: FGEN
Reported as of: 07 Jun 2023
Net transaction value: -$81,367
SEC form: 4
Accepted by SEC: 09 Jun 2023, 19:55:34 UTC
Prior SEC filing: 05 Apr 2023
Next SEC filing: 14 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Cecelia Monoarfa-Taime, Attorney-in-fact

Key filing fact

Aoife Brennan filed Form 4 for FIBROGEN INC (FGEN) on 09 Jun 2023.

Key facts

This page summarizes Aoife Brennan's Form 4 filing for FIBROGEN INC (FGEN).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2023, 19:55.

Change

Previous filing in this sequence was filed on 05 Apr 2023.
Current net transaction value: -$81,367.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FGEN transaction

Common Stock

Award

Transaction value: $0
Shares: +8,289
Change %: +34%
Price: $0.000000
Shares after: 32,680
Date: 07 Jun 2023
Ownership: Direct
Footnotes: F1

FGEN transaction

Common Stock

Sale

Transaction value: $33,380
Shares: -1,994
Change %: -6.1%
Price: $16.74^*
Shares after: 30,686
Date: 09 Jun 2023
Ownership: Direct
Footnotes: F2, F3

FGEN transaction

Common Stock

Sale

Transaction value: $47,987
Shares: -2,739
Change %: -8.9%
Price: $17.52^*
Shares after: 27,947
Date: 09 Jun 2023
Ownership: Direct
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FGEN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +12,666
Change %
Price: $0.000000
Shares after: 12,666
Date: 07 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,666
Exercise price: $17.13
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Footnote F2

Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

Footnote F3

Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.17 to $17.14. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Footnote F4

Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.26 to $17.72. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Footnote F5

Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.